These results indicate that the increase of anti-RBD IgG elicited by XBB.1.5-adapted vaccines translates into increased neutralization against omicron subvariants and is impaired by anti-TNF therapy in patients with IBD. The gene discussed is TNF; the disease is inflammatory bowel disease.